<?xml version='1.0' encoding='utf-8'?>
<document id="27252068"><sentence text="Pharmacokinetic and Pharmacodynamic Analyses of Drug-Drug Interactions between Iguratimod and Warfarin."><entity charOffset="79-89" id="DDI-PubMed.27252068.s1.e0" text="Iguratimod" /><entity charOffset="94-102" id="DDI-PubMed.27252068.s1.e1" text="Warfarin" /><pair ddi="false" e1="DDI-PubMed.27252068.s1.e0" e2="DDI-PubMed.27252068.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27252068.s1.e0" e2="DDI-PubMed.27252068.s1.e1" /></sentence><sentence text="Iguratimod (IGU), a disease-modifying antirheumatic drug launched in September 2012, has been reported to carry a risk of severe hemorrhages through a suspected interaction with warfarin (WF) in the all-case surveillance and early postmarketing-phase vigilance"><entity charOffset="0-10" id="DDI-PubMed.27252068.s2.e0" text="Iguratimod" /><entity charOffset="12-15" id="DDI-PubMed.27252068.s2.e1" text="IGU" /><pair ddi="false" e1="DDI-PubMed.27252068.s2.e0" e2="DDI-PubMed.27252068.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27252068.s2.e0" e2="DDI-PubMed.27252068.s2.e1" /></sentence><sentence text=" To elucidate possible mechanisms of adverse interaction between IGU and WF, we analyzed the effects of IGU on the pharmacodynamics and pharmacokinetics of WF in rats"><entity charOffset="65-67" id="DDI-PubMed.27252068.s3.e0" text="IGU" /><entity charOffset="104-106" id="DDI-PubMed.27252068.s3.e1" text="IGU" /><pair ddi="false" e1="DDI-PubMed.27252068.s3.e0" e2="DDI-PubMed.27252068.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27252068.s3.e0" e2="DDI-PubMed.27252068.s3.e1" /></sentence><sentence text=" IGU was orally administered to male Wistar rats once daily for 5 d at 10 or 30 mg/kg in combination with WF at an oral dose of 0"><entity charOffset="1-3" id="DDI-PubMed.27252068.s4.e0" text="IGU" /></sentence><sentence text="25 mg/kg" /><sentence text=" Coadministration of IGU 30 mg/kg enhanced the anticoagulant activity of WF; prolonged blood coagulation time (prothrombin time and activated partial thromboplastin time) and decreased levels of vitamin K (VK)-dependent blood coagulation factors (II, VII, IX, and X) were observed"><entity charOffset="195-204" id="DDI-PubMed.27252068.s6.e0" text="vitamin K" /><entity charOffset="21-29" id="DDI-PubMed.27252068.s6.e1" text="IGU" /><pair ddi="false" e1="DDI-PubMed.27252068.s6.e1" e2="DDI-PubMed.27252068.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27252068.s6.e1" e2="DDI-PubMed.27252068.s6.e0" /></sentence><sentence text=" On the other hand, the pharmacokinetic parameters of WF including maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from 0 to 24 h (AUC0-24 h) were not affected by the combination with IGU"><entity charOffset="223-225" id="DDI-PubMed.27252068.s7.e0" text="IGU" /></sentence><sentence text=" IGU alone did not change blood coagulation time at doses up to 100 mg/kg, while VK-dependent blood coagulation factors decreased slightly at 30 and 100 mg/kg"><entity charOffset="1-3" id="DDI-PubMed.27252068.s8.e0" text="IGU" /></sentence><sentence text=" These results suggest that the pharmacodynamic effect of IGU on VK-dependent blood coagulation factors is involved in the mechanism of drug-drug interaction of IGU with WF"><entity charOffset="58-60" id="DDI-PubMed.27252068.s9.e0" text="IGU" /><entity charOffset="161-163" id="DDI-PubMed.27252068.s9.e1" text="IGU" /><pair ddi="false" e1="DDI-PubMed.27252068.s9.e0" e2="DDI-PubMed.27252068.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27252068.s9.e0" e2="DDI-PubMed.27252068.s9.e1" /></sentence><sentence text="" /></document>